The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

Dutton Associates Featured Company: Neurobiological Technologies, Inc. (NTII)

 Jul 24, 2008 01:15 AM UTC
Symbol Sentiment Start Return Closed
NTII n/a

Graphic_arrow1 Via StraightStocks:  

Neurobiological Technologies, Inc. (NASDAQ: NTII) is a biopharmaceutical company focused on developing innovative and leading agents for central nervous system conditions and other serious medical conditions. The company seeks out drug candidates related to the central nervous system, and develops therapies for neurological conditions that occur in connection with dementia, Alzheimer’s disease, ischemic stroke, neuropathic pain, and brain cancer. They employ a strategy of in-licensing late-stage CNS agents and strive to gain regulatory approval and commercialization, either independently or with a strategic partner.


Neurobiological Technologies most advanced product candidate is Viprinex??????? (ancrod), a drug for treating acute ischemic stroke. The product is in Phase 3 of clinical testing as a novel investigational drug with multiple mechanisms of action that are specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most common, invigorating, and costly diseases in the world, for which there are few acceptable treatment options. NTI’s pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer’s and Huntington’s diseases.


The company’s other two products include XERECEPT and MEMANTINE (Namenda????). XERECEPT is an original agent being investigated for the treatment of brain swelling associated with brain tumors, and possesses the potential to enhance in functional independence and reduction in required level of care. Currently, the drug is being tested in two pivotal Phase III clinical studies, which are taking place in the United States and Canada. MEMANTINE (Namenda????) will be used to combat moderate to severe dementia and Alzheimer’s disease. NTI has an exclusive marketing arrangement that states they have the right to receive royalty payments from Merz and their marketing partners.


Let us hear your thoughts: Neurobiological Technologies, Inc. Message Board

Tags for this Post:
Market Commentary, OTCBB Markets, Small & Micro Cap, Stocks to Watch


 Graphic_website1 Read the rest of original post »



Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch